


New research projects on Coronavirus (March 2020)

Outcome of emergency funding action for coronavirus SARS-CoV-2 outbreak: 18 new projects

On 30 January 2020, the European Commission launched <u>a</u> request for expressions of interest entitled "SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and public health response to the [COVID-19] epidemic" with a budget of €10 million subsequently increased up to €48.5 million.

Such rapid reaction is made possible by the standing budget line for emergency research funds that the Commission maintains as part of the **Horizon 2020** annual work programmes for Health research.



<u>This enabled 17 projects to be short-listed for funding as the EC announced on 6 March 2020</u>, to which an 18th project was added in late March¹. In total, the 18 projects involve 140 research teams from across the EU and beyond who will work on:

- Improving epidemiology and public health, including our preparedness and response to outbreaks. These projects will help develop better monitoring systems in order to effectively prevent and control the spread of the virus, as well as contribute to the assessment of social dynamics.
- **Rapid point-of-care diagnostic tests**. Increased efforts will concentrate on enabling front-line health workers to make the diagnosis more quickly and more accurately, which will in turn reduce the risk of further spread of the virus.
- **New treatments**, in which a dual approach will be adopted. Firstly, accelerating the development of new treatments currently in the pipeline (including therapeutic peptides, monoclonal antibodies and broadspectrum antivirals), and secondly, screening and identifying molecules that could work against the virus, using advanced modelling and computing techniques.
- **Development of new vaccines**. The research will focus on developing a prophylactic vaccine and a therapeutic vaccine, which will be used for prevention and treatment respectively.

The projects are listed below. Disclaimer: For each project, funding and composition of the consortium is subject to final European Commission decision and signature of Horizon 2020 Grant Agreement.

For more information on EC support for coronavirus-related research.

¹ On 30 March, an 18th proposal was added to the initial shortlist after its evaluation was initially suspended pending the provision of some administrative information.

18 Horizon 2020 research projects on coronavirus short-listed for funding (March 2020)

Epidemiology			
Acronym	Title	Lead partner institution	All partners
I-MOVE-COVID-19	Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic	Epiconcept (FR)	20 partners: AL, DE, ES(2), FR(5), IE, LT, NL(2), PT(2), RO, SE, UK(2)
RECOVER	Rapid European COVID-19 Emergency research Response	Universiteit Antwerpen (BE)	10 partners: BE, CN, DE, FR(2), IT, NL(3), UK
<u>HERoS</u>	Health Emergency Response in Interconnected Systems	Svenska handelshögskolan (FI)	11 partners: FR, FI(2), IT, MK, NL(2), PL(3), UK
EpiPose	Epidemic intelligence to minimize 2019- nCoV's public health, economic and social impact in Europe	Universiteit Hasselt (BE)	6 partners: BE(2), CH, IT, NL, UK
CORESMA	COVID-19-Outbreak Response combining E-health, Serolomics, Modelling, Artificial Intelligence and Implementation Research	Helmholtz-Zentrum für Infektionsforschung (DE)	7 partners: CH, CI, CN, DE(2), NL, NP
Modelling			
RiPCoN	Rapid interaction profiling of 2019-nCoV for network-based deep drug- repurpose learning (DDRL)	Helmholtz Zentrum München Deutsche Forschungszentrum für Gesundheit und Umwelt (DE)	3 partners: DE, ES, FR
EXSCALATE4CoV	EXaSCale smArt pLatform Against paThogEns for Corona Virus	Dompé farmaceutici (IT)	18 partners: BE, CH(2), DE(2), ES, IT(10), PL, SE
Diagnostics			
CoNVat	Combating 2019-nCoV: Advanced Nanobiosensing platforms for POC global diagnostics and surveillance	Fundacio Institut Catala de Nanociencia i Nanotecnologia (ES)	4 partners: ES(2), FR, IT
CoronaDX	Three Rapid Diagnostic tests (Point-of-Care) for COVID-19 Coronavirus, improving epidemic preparedness, public health and socio-economic benefits	Danmarks Tekniske Universitet (DK)	8 partners: AT, CN(2), DK(2), IT(2), SE
HG nCoV19 test	Development and validation of rapid molecular diagnostic test for nCoV19	Hibergene Diagnostics (IE)	4 partners: CN, IE, IT, UK

Treatment			
Fight-nCoV	Fighting-off Coronavirus (SARS-CoV-2) with broad-spectrum antivirals: establishing animal challenge model	Stockholms Universitet (SE)	6 partners: DE(2), DK, FR, SE(2)
<u>SCORE</u>	Swift COronavirus therapeutics Response	Academisch Ziekenhuis Leiden (NL)	8 partners: BE(2), CH, DE(2), FR, NL(2)
Solnatide	Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus	APEPTICO Forschung und Entwicklung GmbH (AT)	5 partners: AT, DE, ES, IT, NL,
ATAC	Antibody therapy against coronavirus (COVID-2019)	Karolinska Institutet (SE)	5 partners: BE, CH, DE, IT, SE
MANCO	Monoclonal Antibodies against 2019- New Coronavirus	Harbour Antibodies BV (NL)	8 partners: DE, ES, FR(2), NL(4)
<u>CoroNAb</u>	Nanobodies and antibodies against 2019- nCoV	Karolinska Institutet (SE)	4 partners: CH, DK, SE, UK
Vaccines			
<u>OPENCORONA</u>	Rapid therapy development through Open Coronavirus Vaccine Platform	Karolinska Institutet (SE)	7 partners: DE, IT, SE(5)
Prevent-nCoV	Prevention of 2019 nCoV infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine	AdaptVac (DK)	6 partners: DE, DK(3), NL(2)

To contact the project lead partners of the shorted-listed proposals: $\underline{\text{RTD-CORONAVIRUS@ec.europa.eu}}$